GEN1107

PreclinicalSmall molecule

GEN1107 is one of 38 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsTerminated

Patients With Advanced Solid TumorsPreclinical

Terminated

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Halaven

Eisai

Phase 2

2 2

Ensacove

XXcovery Holdings, Inc.

Phase 2

1 3

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

2 4

Carboplatin AUC-5

Merck & Co.

Phase 2

1 5

HRS-4642

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

2 6

ZG005

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2

2 7

AK112

SSummit Therapeutics

Phase 2

1 8

Almonertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 2

1 9

QL2107

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 10

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors

Terminated· Genmab logo

Genmab·Preclinical·NCT06171789·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GEN1107. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GEN1107 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GEN1107. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Genmab

GEN1107

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endometrial Cancer1 trial

References

Drug Info

Quick Facts

Related News